Abstract:Abstract Cancer cells apply metabolic adaptations for proliferation and survival such as the Warburg Effect and the maintenance of redox balance, which are common for different cancer types. However, it remains elusive whether different cancer oncogenic backgrounds require oncogene-specific metabolic adaptations, which could represent unique cancer vulnerabilities for novel therapy development. Herein we report that, using a shRNA library designed to target a subset of genes related to cell metabolism, we identified adenosylhomocysteinase like 1 (AHCYL1) as a “synthetic lethal” partner of oncogenic NRAS mutations, which is selectively important for the proliferation and survival of NRAS mutant-expressing melanoma cells, but not for cells harboring BRAF mutations. AHCYL1 is an inhibitory binding partner of endoplasmic reticulum (ER) calcium channel protein inositol trisphosphate receptor (IP3R) by competing off its agonist inositol triphosphate (IP3) and consequently blocking ER calcium release. In consonance with our finding, AHCYL1 expression levels correlate with mutational status of NRAS but not with BRAF in diverse human melanoma cell lines. In addition, exogenous expression of mutant NRAS but not BRAF in immortal melanocytes MEL-ST cells results in upregulated AHCYL1 transcription and protein expression. Notably, these findings are consistent with the results of Cancer Genome Atlas (TCGA) database analysis, which reveal elevated AHCYL1 transcription in melanoma patients harboring NRAS mutations but not BRAF V600E mutation. Further transcription factor screening studies suggested that the transcription of AHCYL1 is regulated by activating transcription factor 2 (ATF2), which is supported by TCGA database analysis results showing that ATF2 transcription level is selectively higher in NRAS-mutant melanoma patients. Furthermore, AHCYL1-deficiency by shRNA-mediated knockdown and CRISPR/Cas9-mediated knockout significantly reduces in vitro cell proliferation and in vivo tumor growth potential of NRAS mutant-expressing melanoma cells, but not for control melanoma cells expressing BRAF V600E mutant. Mechanistically, AHCYL1 deficiency in NRAS mutant-expressing melanoma cells triggers calcium leakage from the ER, leading to sustained activation of the ER unfolded protein response (UPR) that subsequently attenuates cell proliferation and initiates apoptosis. Altogether, these findings suggest a positive feedback mechanism by which mutant NRAS enhances AHCYL1 expression that contributes to NRAS mutation-dependent melanoma transformation and tumor growth. The AHCYL1-IP3R axis may represent a novel therapeutic target for treatment of NRAS mutant-expressing tumors including melanoma. Citation Format: Chufan Cai, Jiayi Tu, Jeronimo Najarro, Rukang Zhang, Xue Gao, Hao Fan, Freya Zhang, Jiacheng Li, Michele Ciboddo, Shannon Elf, Rong Wu, Jing Chen. AHCYL1 is crucial for NRAS mutant-expressing melanoma tumor growth by governing ER calcium homeostasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 283.

ATAD3A mediates activation of RAS-independent mitochondrial ERK1/2 signaling, favoring head and neck cancer development

Identification of ATAD3A As a Key Regulator in Non-Small Cell Lung Cancer by Promoting STAT3-induced Cell Proliferation and Tumor Angiogenesis

Tumor-Promoting ATAD2 and Its Preclinical Challenges

ATAD3B is a Mitophagy Receptor Mediating Clearance of Oxidative Stress‐induced Damaged Mitochondrial DNA

Adrenomedullin is a Novel K-RAS Target Gene That Regulates Cellular Invasion and Angiogenesis in Hypoxia

Abstract 59: LNP-CRISPR Gene Editing Enables in Vivo ATAD3A Depletion and Induces the Remission of Head and Neck Cancer

Abstract 1219: In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables ATAD3A gene depletion to enhance RAS-targeted therapy

ATAD2 Promotes Glycolysis and Tumor Progression in Clear Cell Renal Cell Carcinoma by Regulating the Transcriptional Activity of C-Myc

Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis

RAS/MAPK Activation is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

ATAD3 is a limiting factor in mitochondrial biogenesis and adipogenesis of white adipocyte‐like 3T3‐L1 cells

TAF1D promotes tumorigenesis and metastasis by activating PI3K/AKT/mTOR signaling in clear cell renal cell carcinoma

ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling

Targeting STT3A Produces an Anti-Tumor Effect in Lung Adenocarcinoma by Blocking the MAPK and PI3K/AKT Signaling Pathway.

NRAS mutant dictates AHCYL1-governed ER calcium homeostasis for melanoma tumor growth

Atad2 Overexpression Identifies Colorectal Cancer Patients With Poor Prognosis And Drives Proliferation Of Cancer Cells

ALDH1L2 Drives HCC Progression Through TAM Polarization

Sirt3 Overexpression Inhibits Growth Of Kidney Tumor Cells And Enhances Mitochondrial Biogenesis

Abstract 283: AHCYL1 is crucial for NRAS mutant-expressing melanoma tumor growth by governing ER calcium homeostasis

Knockdown of Lncrna NEAT1 Suppresses Hypoxia-Induced Migration, Invasion and Glycolysis in Anaplastic Thyroid Carcinoma Cells Through Regulation of Mir-206 and Mir-599

Transcriptional Adaptor 3 Influences the Proliferative and Invasive Phenotypes of Non-Small Cell Lung Cancer Cells Via Regulating EMT.